Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: Long-term follow-up

Journal of Bone and Joint Surgery

Volumn 95, Issue 12, 2013, Pages 1057-1061

  Lebel, David E ^a   Corston, John A ^a   McAdam, Laura C ^b   Biggar, W Douglas ^b   Alman, Benjamin A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEFLAZACORT; GLUCOCORTICOID; PREGNANE DERIVATIVE;

ARTICLE; BODY WEIGHT DISORDER; CARDIOMYOPATHY; CATARACT; CATARACT EXTRACTION; CHEMOPROPHYLAXIS; CHILD; CHILDHOOD DISEASE; COBB ANGLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEATH; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SAFETY; DRUG WITHDRAWAL; DUCHENNE MUSCULAR DYSTROPHY; FAMILY ATTITUDE; FOLLOW UP; FRACTURE; GROUPS BY AGE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; LONG BONE FRACTURE; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RISK ASSESSMENT; SCHOOL CHILD; SCOLIOSIS; SPINE SURGERY; SURVIVAL; SURVIVAL RATE; SURVIVOR; KAPLAN MEIER METHOD; LONG TERM CARE; TREATMENT OUTCOME;

CHILD; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; KAPLAN-MEIER ESTIMATE; LONG-TERM CARE; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PREGNENEDIONES; SCOLIOSIS; TREATMENT OUTCOME;

EID: 84882267702     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.L.01577     Document Type: Article

References (21)

1. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010 Feb;9(2):177-89.
2. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010 Jan;9(1):77-93.
3. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2008;(1):CD003725.
4. Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve. 2007 Oct;36(4):424-35.
5. O'Brien KF, Kunkel LM. Dystrophin and muscular dystrophy: past, present, and future. Mol Genet Metab. 2001 Sep-Oct;74(1-2):75-88.
6. Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP; Clinical Investigation of Duchenne Dystrophy Group. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Arch Neurol. 1991 Apr;48(4):383-8.
7. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, King W, Signore L, Pandya S, Florence J, Schierbecker J, Robison J, Kaiser K, Mandel S, Arfken C, Gilder B. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989 Jun 15;320(24):1592-7.
8. Campbell C, Jacob P. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review. BMC Neurol. 2003 Sep 8;3:7.
9. Arizón JM, Anguita M, Vallés F, Montero A, Sancho M, López-Rubio F, Latre JM, Calleja F, Casares J, Román M. Preliminary experience with deflazacort, a new synthetic steroid with fewer undesirable side effects, in heart transplant patients. J Heart Lung Transplant. 1993 May-Jun;12(3):445-8; discussion 448-9.
10. Bonifati MD, Ruzza G, Bonometto P, Berardinelli A, Gorni K, Orcesi S, Lanzi G, Angelini C. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve. 2000 Sep;23(9): 1344-7.
11. Biggar WD, Politano L, Harris VA, Passamano L, Vajsar J, Alman B, Palladino A, Comi LI, Nigro G. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord. 2004 Sep;14(8-9):476-82.
12. Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001 Jan;138(1):45-50.
13. Alman BA, Raza SN, Biggar WD. Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. J Bone Joint Surg Am. 2004 Mar;86(3):519-24.
14. Smith AD, Koreska J, Moseley CF. Progression of scoliosis in Duchenne muscular dystrophy. J Bone Joint Surg Am. 1989 Aug;71(7):1066-74.
15. Alman BA, Kim HK. Pelvic obliquity after fusion of the spine in Duchenne muscular dystrophy. J Bone Joint Surg Br. 1999 Sep;81(5):821-4.
16. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006 Apr;16(4):249-55.
17. Dooley JM, Gordon KE, MacSween JM. Impact of steroids on surgical experiences of patients with Duchenne muscular dystrophy. Pediatr Neurol. 2010 Sep;43(3):173-6.
18. Houde S, Filiatrault M, Fournier A, Dubé J, D'Arcy S, Bérubé D, Brousseau Y, Lapierre G, Vanasse M. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol. 2008 Mar;38(3):200-6.
19. King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, Mendell JR, Kissel JT. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007 May 8;68(19):1607-13.
20. Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil. 2005 Nov;84(11):843-50.
21. Kinali M, Main M, Eliahoo J, Messina S, Knight RK, Lehovsky J, Edge G, Mercuri E, Manzur AY, Muntoni F. Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2007 May;11(3):160-6.